Clinical Trials Logo

Urinary Bladder Neoplasms clinical trials

View clinical trials related to Urinary Bladder Neoplasms.

Filter by:

NCT ID: NCT00014144 Completed - Bladder Cancer Clinical Trials

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Start date: February 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have advanced cancer of the urinary tract.

NCT ID: NCT00011518 Completed - Bladder Cancer Clinical Trials

Bladder Cancer Case Control Study of Arsenic in Water

Start date: October 1997
Phase: N/A
Study type: Observational

This study is examining the relationship between ingested arsenic and bladder cancer in two areas of California where a large percentage of the population was exposed to drinking water containing arsenic at low to moderate levels.

NCT ID: NCT00009867 Completed - Clinical trials for Transitional Cell Carcinoma of the Bladder

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Start date: December 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent cancer of the bladder or urinary tract. Arsenic trioxide may kill tumor cells that have become resistant to standard chemotherapy regimens.

NCT ID: NCT00006476 Completed - Bladder Cancer Clinical Trials

Suramin in Treating Patients With Recurrent Bladder Cancer

Start date: October 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Suramin may stop the growth of bladder cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of suramin in treating patients who have recurrent bladder cancer.

NCT ID: NCT00006376 Completed - Bladder Cancer Clinical Trials

R115777 in Treating Patients With Advanced Bladder Cancer

Start date: March 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have advanced bladder cancer.

NCT ID: NCT00006351 Completed - Bladder Cancer Clinical Trials

SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract

Start date: June 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SCH 66336 and gemcitabine may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of SCH 66336 plus gemcitabine in treating patients who have advanced cancer of the urinary tract.

NCT ID: NCT00006124 Completed - Clinical trials for Recurrent Bladder Cancer

Celecoxib in Treating Patients With Bladder Cancer

Start date: June 2000
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of bladder cancer

NCT ID: NCT00006111 Completed - Bladder Cancer Clinical Trials

Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract

Start date: April 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining surgery with chemotherapy and radiation therapy may be an effective way to treat cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of combining surgery, chemotherapy and radiation therapy in treating patients who have stage II, stage III, or stage IV cancer of the urinary tract .

NCT ID: NCT00006105 Completed - Bladder Cancer Clinical Trials

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

Start date: June 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine, cisplatin, and amifostine following surgery in treating patients who have locally advanced bladder cancer.

NCT ID: NCT00006034 Completed - Bladder Cancer Clinical Trials

Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer

Start date: June 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether keyhole limpet hemocyanin is more effective than doxorubicin for bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of keyhole limpet hemocyanin with that of doxorubicin in treating patients who have bladder cancer that has not responded to BCG or in those patients who cannot tolerate BCG.